Genmab — April 2017

[jkj]

Ved det er i dag, men klokken hvad ?

[E_L]

just available now, via https://iplanner.asco.org/am2017/#/

[jkj]

thanks EL

[E_L]

for dara i think 2 oral and 6 poster board, for ofa 1 poster board

[E_L]

Abstract TPS2605
GCT1021-01, a first-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (HuMax-Axl-ADC) in patients with solid tumors (NCT02988817).

[E_L]

Poster board, but that study only just started...

[jkj]

Den er spændende, det er abstrackt 8000 også Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001): An open-label, phase 1b study. )

[jkj]

Den her skal der også holdes øje med. Abstract TPS9102
Randomized, open-label phase Ib/II study of atezolizumab with or without daratumumab in previously treated advanced or metastatic non-small cell lung cancer (NSCLC).

[E_L]

is 8000 NCT01998971 ? that has Primary Compl.
date on 30june

[E_L]

8006 is Cassiopeia i guess ? that is the 2nd oral

[E_L]

8036 is Castor

[E_L]

Genmab Announces Data to be Presented at 2017 ASCO Annual Meeting http://ir.genmab.com/releasedetail.cfm?ReleaseID=1022126

[E_L]

I think Genmab only announcing the Janssen based studies, not even mentioning ofa study lol

[Darvin]

1313

[JKY_VH]

respekt bibob:-)

[transalp]

Vismand bob..

[bibob]

[bibob]

Dejligt at kravle over 1300 igen.

[JKY_VH]

vi ser frem til næste pletskud:-)

[bibob]

Ja ,- bare det så ikke er sydpå. Det går lidt hurtigere den vej.